Nirsevimab Shows High Effectiveness Against RSV in Children
A new study reveals 75% effectiveness for RSV immunizations in high-risk children during their second season.
Updated on Oct. 22, 2026 in Children’s Health
Live Poll
Does evidence of immunization effectiveness increase your trust in current public health recommendations for children?
Data released in March 2026 shows nirsevimab immunizations are 75% effective at preventing RSV-associated hospitalizations in high-risk children during their second RSV season. The study, conducted across the United States, supports the American Academy of Pediatrics' decision to expand eligibility criteria for the immunization.
Why it matters
The findings provide essential real-world evidence for protecting high-risk children who remain vulnerable to RSV beyond their first year of life. This validation helps clinicians refine immunization strategies to better safeguard pediatric patients during peak respiratory virus seasons.
The study observed 231 nirsevimab-eligible hospitalized children across 26 U.S. hospitals. Estimated effectiveness reached 86% when the immunization was administered within 60 days of symptom onset, compared to 66% for earlier administration.
The players
American Academy of Pediatrics
This professional organization of pediatricians sets clinical guidelines and policy recommendations for the health and well-being of infants, children, and adolescents.
The details
Researchers utilized caregiver interviews and medical record abstraction to track children with respiratory symptoms across two seasons. While RSV-positive children showed a 36% rate of acute respiratory failure, the study recorded zero deaths among those hospitalized with the virus.
Timeline
The study covered two RSV seasons spanning from November 2024 to March 2026.
Health Landscape
This research follows the established trajectory of pediatric preventative medicine by providing clinical validation for the American Academy of Pediatrics immunization guidelines. It marks a significant milestone in expanding protective measures beyond the first year of life for high-risk populations.
Families with high-risk children should consult their pediatricians regarding updated second-season RSV immunization eligibility. Understanding that administration within 60 days of potential exposure yields higher protection can help parents and doctors better time these health routines.
The takeaway
Proactive immunization timing remains a critical factor for maximizing protection against severe RSV complications. Parents should coordinate with healthcare providers to ensure their children meet the criteria for second-season coverage before peak viral months begin.
Further reading
For more on pediatric care and virus prevention, visit the Children’s Health section.
Source note: This article includes information reported by MedPage Today.
Live Poll
Does evidence of immunization effectiveness increase your trust in current public health recommendations for children?
